Steel, D H W
Downey, L
Greiner, K
Heimann, H
Jackson, T L
Koshy, Z
Laidlaw, D A H
Wickham, L
Yang, Y
Article History
Received: 8 July 2015
Accepted: 13 October 2015
First Online: 15 January 2016
Competing interests
: This study group was convened by Alcon, which distributes ocriplasmin in the UK on behalf of Thrombogenics. Neither Thrombogenics nor Alcon had input in the design of the study, manuscript preparation, or editorial review and neither were invited to review the manuscript prior to submission. Steel DHW is a consultant to Alcon and advisor to Novartis and Bayer. Jackson TL is a consultant to Thrombogenics and advisor to Alcon, Bausch & Lomb, and DORC. Yang Y is a consultant to Bayer and Alimera Sciences and advisor to Alcon, Thrombogenics, Allergan, and Novartis. Downey L, Laidlaw DAH, Koshy Z, Heimann H, Wickham L, and Greiner K have acted as advisors to Alcon and Thrombogenics regarding ocriplasmin.